Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1–Selected Advanced Non–Small-Cell Lung Cancer (BIRCH)

PURPOSE: BIRCH was designed to examine the efficacy of atezolizumab, a humanized anti–programmed death-ligand 1 (PD-L1) monoclonal antibody, in advanced non–small-cell lung cancer (NSCLC) across lines of therapy. Patients were selected on the basis of PD-L1 expression on tumor cells (TC) or tumor-in...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Clin Oncol
Autors principals: Peters, Solange, Gettinger, Scott, Johnson, Melissa L., Jänne, Pasi A., Garassino, Marina C., Christoph, Daniel, Toh, Chee Keong, Rizvi, Naiyer A., Chaft, Jamie E., Carcereny Costa, Enric, Patel, Jyoti D., Chow, Laura Q.M., Koczywas, Marianna, Ho, Cheryl, Früh, Martin, van den Heuvel, Michel, Rothenstein, Jeffrey, Reck, Martin, Paz-Ares, Luis, Shepherd, Frances A., Kurata, Takayasu, Li, Zhengrong, Qiu, Jiaheng, Kowanetz, Marcin, Mocci, Simonetta, Shankar, Geetha, Sandler, Alan, Felip, Enriqueta
Format: Artigo
Idioma:Inglês
Publicat: American Society of Clinical Oncology 2017
Matèries:
ORIGINAL REPORTS
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC5562171/
https://ncbi.nlm.nih.gov/pubmed/28609226
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1200/JCO.2016.71.9476
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars